Journal article
Nivolumab for second-line treatment of metastatic squamous non-small-cell lung cancer
American journal of health-system pharmacy, Vol.72(21), pp.1851-1855
11/01/2015
DOI: 10.2146/ajhp150235
PMID: 26490818
Abstract
Purpose. The pharmacokinetics, pharmacodynamics, efficacy, toxicity, and place in therapy of nivolumab, a novel immunotherapy agent for the treatment of advanced non-small-cell lung cancer (NSCLC) of the squamous cell subtype are reviewed.
Summary. Nivolumab is a novel programmed cell death 1 (PD-1) immune checkpoint inhibitor indicated as a second-line treatment for patients with NSCLC whose tumors exhibit squamous cell histology. Nivolumab has high affinity for the PD-1 receptor, and durable responses to treatment have been reported in clinical trials. In a Phase II study evaluating the drug's safety and efficacy in patients who had disease progression despite treatment with platinum-based doublet chemotherapy and at least one additional systemic therapy, nivolumab-treated patients had an objective response rate of 14.5%, with a 17% rate of grade 3 or 4 treatment-related adverse events; overall survival at one year was 40.8%. A head-to-head comparison of docetaxel and nivolumab for second-line treatment of squamous cell NSCLC demonstrated superior overall survival and reduced grade 3 or 4 adverse effects in nivolumab-treated patients.
Conclusion. Nivolumab is a novel PD-1 immune checkpoint inhibitor that is effective for treating advanced squamous NSCLC in patients previously treated with platinum-based doublet chemotherapy or alternative first-line agents. Based on its improved efficacy and lower toxicity relative to docetaxel, nivolumab should be considered standard second-line therapy for this population.
Details
- Title: Subtitle
- Nivolumab for second-line treatment of metastatic squamous non-small-cell lung cancer
- Creators
- Amanda Rounds - University of Wisconsin–MadisonJill Kolesar - University of Wisconsin Carbone Cancer Center
- Resource Type
- Journal article
- Publication Details
- American journal of health-system pharmacy, Vol.72(21), pp.1851-1855
- Publisher
- Oxford Univ Press
- DOI
- 10.2146/ajhp150235
- PMID
- 26490818
- ISSN
- 1079-2082
- eISSN
- 1535-2900
- Number of pages
- 5
- Language
- English
- Date published
- 11/01/2015
- Academic Unit
- Pharmacy; Pharmaceutical Sciences and Experimental Therapeutics
- Record Identifier
- 9984695793002771
Metrics
1 Record Views